Large study evaluates cholinesterase inhibitor use

Cholinesterase inhibitor use is associated with cognitive benefits that are modest but persist over time, according to new findings from a large registry study.

Researchers from the Karolinska University Hospital and Karolinska Institutet, in Huddinge, Sweden, analyzed longitudinal data from the Swedish Dementia Registry to investigate whether cholinesterase inhibitors are associated with less cognitive decline in AD and a reduced risk of severe dementia or death.

The study population comprised 11,652 AD patients who were started on a cholinesterase inhibitor within 3 months of being diagnosed with dementia, and 5,826 matched non-treated patients.